Why the study?
Does recombinant human erythropoietin therapy increase plasma endothelin-1 levels in hemodialysis patients who develop hypertension?
Population
16 hemodialysis patients, mean age 54±3 years
Comparison
Recombinant human erythropoietin 30-120… vs Baseline values before therapy and comparison…
Design
Cohort
Follow-up
12 weeks
Authors
Loading...
Endothelin-1 rise was associated with erythropoietin-related hypertension in hemodialysis; leaves open causality pending randomized confirmation.
Does recombinant human erythropoietin therapy increase plasma endothelin-1 levels in hemodialysis patients who develop hypertension?
Increased plasma endothelin-1 levels correlate with the development of hypertension in hemodialysis patients receiving erythropoietin therapy, suggesting a pathogenic role.
Naruse et al. (1992) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: